The DECIDE-TB Trial; Validation of Treatment Decision Algorithms for Childhood Tuberculosis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeUp to 14
SponsorChishala Chabala

About this trial

The Decide-TB project aims to generate evidence for the implementation of a comprehensive Treatment Decision Algorithms (TDA) based approach for TB in children living in high TB burden and resource-limited countries, at District Hospital (DH) and Primary Health Centre (PHC) levels, and to facilitate the integration of this evidence within practices and policies.

This programmatic pilot led by the National TB Programs (NTP) will test a TDA-based approach integrating TB screening, diagnosis, treatment decision-making, and disease severity assessment for shorter treatment eligibility, for use at a lower level of healthcare. This TDA-based approach will be evaluated in a hybrid effectiveness implementation study based on a pragmatic stepped wedge cluster-randomized trial. The Decide TB project will be implemented at the district level, targeting five districts in each country. Each cluster in a district will be made up of one district hospital and six primary health centers. The study will develop a Clinical Decision Support System (CDSS) to operationalize the use of TDAs, and strengthen District Health Information Systems (DHIS2) to collect individual data, which will contribute to monitoring and evaluation, clinical mentoring, and supervision by the country's NTPs.

Eligibility criteria

Qualifiers

All sick children aged below 15 years entering the selected health facilities (DH and PHC) at either outpatient (OPD) or inpatient (IPD) departments, including children from high-risk groups, as well as children identified as contact of TB cases through community- or facility-based household contact tracing.

Children with presumptive TB.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • The comprehensive TDA based approach

Treatment groups

30,240 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Chishala Chabala

Lead sponsor

University of Zambia

Sponsor institution

University of Bordeaux

Collaborator

Instituto Nacional de Saúde, Mozambique

Collaborator

ADERA

Collaborator

University of Stellenbosch

Collaborator

Imperial College London

Collaborator

Institut de Recherche pour le Développement (IRD)

Collaborator

University of Sheffield

Collaborator

Ludwig-Maximilians - University of Munich

Collaborator

Ministry of Health, Zambia

Collaborator

Ministry of Health, Mozambique

Collaborator

Eduardo Mondlane University

Collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

Collaborator